Gemcitabine - nabpaclitaxel

PreclinicalSmall molecule

GGalician Research Group on Digestive Tumors

Gemcitabine - nabpaclitaxel is one of 4 small molecule programs targeting Pancreatic Carcinoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic CarcinomaActive, not recruiting

Pancreatic CarcinomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Pancreatic Carcinoma

#DrugCompanyPhaseTrials

Lynparza

AstraZeneca

Approved

—2

Gallium Ga 68 Fapi-46

JJonsson Comprehensive Cancer Center

Phase 2

1 3

Invokana

WWim Janssens

Preclinical

1 4

Gemcitabine - nabpaclitaxel

GGalician Research Group on Digestive Tumors

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pancreatic Carcinoma1 trial

Gemcitabine and Nabpaclitaxel in Metastatic Pancreatic Carcinoma.

Completed·GGalician Research Group on Digestive Tumors··NCT03620461·210 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Gemcitabine - nabpaclitaxel. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Gemcitabine - nabpaclitaxel compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Gemcitabine - nabpaclitaxel. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Galician Research Group on Digestive Tumors company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: GGalician Research Group on Digestive Tumors

Gemcitabine - nabpaclitaxel

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pancreatic Carcinoma1 trial

References

Drug Info

Quick Facts

Related News